AUS
NZ
UK
CA
USA
IND
Highlights:
- U.S. DoD Pilot Program: 4D Medical has secured a pilot program with the U.S. Department of Defense to use its CT:VQ lung scanning technology, a major step toward formal FDA approval.
- $1 Billion Market Opportunity: The company aims to replace over one million nuclear VQ scans performed annually, potentially disrupting a billion-dollar industry.
- Targeting Military Health Services: The pilot program will involve active military personnel, with 80 patients in the first trial to assess the technology’s capabilities for detecting lung conditions.
4D Medical Ltd (ASX:4DX) has announced a major milestone for its CT:VQ lung scanning technology, entering into a U.S. Department of Defense (DoD)-funded pilot program that could lead to a formal submission for FDA approval. The company sees this pilot as a critical opportunity to displace the one million nuclear ventilation/perfusion (VQ) scans performed annually, positioning its radioisotope-free technology to tap into a billion-dollar market.
U.S. Department of Defense Partnership
The pilot program with the U.S. DoD is a significant development for 4D Medical, especially given the company’s long-standing relationship with the U.S. military. Previous studies focused on veterans who had experienced lung damage from 'burn pits,' while this new pilot targets active military personnel. The opportunity is particularly compelling due to the extensive reach of the U.S. Military Health Service (MHS), which oversees more than 200 military hospitals and clinics globally.
4D Medical’s CT:VQ technology is positioned to provide a safer, more efficient method of lung imaging without the use of radioisotopes. The $1.9 million grant the company secured to develop this technology underscores its potential in revolutionizing lung diagnostics.
The Pilot and Future Prospects
The DoD's commercial pilot program will involve 80 patients in its first phase. While the initial scale is small, the broader potential for 4D Medical lies in the success of this pilot. If deemed successful, the technology could be integrated into the U.S. military’s healthcare system, which provides vital, high-quality care to ensure the readiness and resilience of the U.S. Armed Forces.
4D Medical's CT:VQ scanning technology is designed for the early detection of multiple lung conditions, including chronic obstructive pulmonary disease (COPD) and chronic thromboembolic pulmonary hypertension. The company aims to leverage this capability to address pressing health issues among military personnel.
4D Medical shares were last traded at 49.5 cents.
